The FDA's approval of Epidiolex for treating epilepsy, backed by high-quality clinical trial data and minimal abuse potential, influenced the DEA's decision to consider rescheduling marijuana.
[
add
]
[
|
|
...
]
The FDA's approval of Epidiolex for treating epilepsy, backed by high-quality clinical trial data and minimal abuse potential, influenced the DEA's decision to consider rescheduling marijuana.